Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 22;13(16):4963.
doi: 10.3390/jcm13164963.

Interstitial Lung Disease Phenotypes and Predictive Risk Factors in Primary Sjögren's Syndrome

Affiliations

Interstitial Lung Disease Phenotypes and Predictive Risk Factors in Primary Sjögren's Syndrome

Gaetano La Rocca et al. J Clin Med. .

Abstract

Background/Objectives: The prevalence of Interstitial Lung Disease (ILD) and risk factors for its development in patients with primary Sjögren's syndrome (pSS) are still debated, possibly due to the existence of heterogeneous pSS-related ILD phenotypes. The aims of this study were: 1. To investigate the prevalence and predictive factors for ILD development in a single-center pSS cohort; 2. To characterize different pSS-ILD phenotypes. Methods: Clinical, laboratory and imaging data of pSS patients attending our center from January 2019 to September 2023 were retrospectively analyzed. ILD presence was confirmed on HRCT. Results: Forty-three out of 474 enrolled pSS patients presented ILD (M:F = 6:37), accounting for an overall ILD prevalence of 9.1%. In 19 cases, ILD was the first manifestation of pSS (ILD-onset), while in 24 ILD was diagnosed after pSS (ILD-incident). Compared to ILD-onset, ILD-incident patients more often presented pSS-related hematologic abnormalities (p = 0.012), cutaneous involvement (p = 0.027), inflammatory arthralgias (p = 0.026), C4 hypocomplementemia (p = 0.012) and positive RF (p = 0.031). On the other hand, ILD-onset patients were significantly older at pSS diagnosis (p = 0.008) and presented more severe fibrosis on HRCT (p = 0.008). On the univariate analysis, higher ESSDAI (p = 0.011), Raynaud's phenomenon (p = 0.009), anti-Ro52 (p = 0.031), hypergammaglobulinemia (p = 0.011), Rheumatoid Factor (RF) (p = 0.038) and C4 hypocomplementemia (p = 0.044) at baseline were associated to ILD development during follow-up. On the multivariate analysis, the ESSDAI at baseline (p = 0.05) and Raynaud's phenomenon (p = 0.013) at baseline were the only independent predictors of ILD development. Conclusions: ILD is a relatively common and clinically heterogenous pSS manifestation. Elevated disease activity at pSS onset is a risk factor for ILD development, prompting careful follow-up and intriguingly suggesting that immunomodulatory therapies may prevent ILD.

Keywords: HRCT patterns; clinical phenotypes; interstitial lung disease; primary Sjögren’s syndrome; prognosis; risk factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Graph showing the extent and severity of fibrosis according to Warrick score in pSS-ILD patients with different HRCT patterns. NSIP = interstitial pneumonia; UIP = usual interstitial pneumonia; OP = organizing pneumonia; LIP = lymphocytic interstitial pneumonia; NC = unclassifiable.
Figure 2
Figure 2
Kaplan-Meier curve showing the different latency from pSS diagnosis to ILD diagnosis between seronegative pSS ILD patients and anti-Ro52 + pSS ILD patients.
Figure 3
Figure 3
Kaplan-Meier curve showing the different latency from pSS diagnosis to ILD diagnosis between LIP patients and pSS-ILD patients with other HRCT patterns.

References

    1. Mariette X., Criswell L.A. Primary Sjögren’s Syndrome. N. Engl. J. Med. 2018;378:931–939. doi: 10.1056/NEJMcp1702514. - DOI - PubMed
    1. Longhino S., Chatzis L.G., Dal Pozzolo R., Peretti S., Fulvio G., La Rocca G., Navarro Garcia I.C., Orlandi M., Quartuccio L., Baldini C. Sjögren’s syndrome: One year in review 2023. Clin. Exp. Rheumatol. 2023;41:2343–2356. doi: 10.55563/clinexprheumatol/255qsx. - DOI - PubMed
    1. Ramos-Casals M., Brito-Zerón P., Seror R., Bootsma H., Bowman S.J., Dörner T., Gottenberg J.E., Mariette X., Theander E., Bombardieri S., et al. Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology. 2015;54:2230–2238. doi: 10.1093/rheumatology/kev200. - DOI - PMC - PubMed
    1. Luppi F., Sebastiani M., Silva M., Sverzellati N., Cavazza A., Salvarani C., Manfredi A. Interstitial lung disease in Sjögren’s syndrome: A clinical review. Clin. Exp. Rheumatol. 2020;38((Suppl. S126)):291–300. - PubMed
    1. Flament T., Bigot A., Chaigne B., Henique H., Diot E., Marchand-Adam S. Pulmonary manifestations of Sjögren’s syndrome. Eur. Respir. Rev. 2016;25:110–123. doi: 10.1183/16000617.0011-2016. - DOI - PMC - PubMed

LinkOut - more resources